Key Takeaway: The e-poster presented by Di Caro et al. at the AD/PD™ 2024 conference highlights the identification of new pharmacodynamic biomarkers associated with CT1812. These biomarkers show a correlation with favorable functional connectivity in the brain, suggesting potential implications for Alzheimer's and Parkinson's disease treatments.
Price reaction · baseline $1.94 (2024-03-04 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close · peak
+8.2%
day 1
+5.2%
day 3
+1.5%
Market Sentiment Analysis
POSITIVE FACTORS
Identification of new pharmacodynamic biomarkers.
Correlation with favorable functional connectivity of the brain.
Presentation at a significant conference.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Di Caro V, Pandey K, Cho E, et al. Identification of New Pharmacodynamic Biomarkers of CT1812 that Correlate with Favorable Functional Connectivity of the Brain . e-Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference ; Lisbon, Portugal.
Frequently Asked Questions
What was presented at the AD/PD™ 2024 conference?
New pharmacodynamic biomarkers of CT1812 were presented.
What do the biomarkers correlate with?
They correlate with favorable functional connectivity of the brain.
Who conducted the research on CT1812?
The research was conducted by Di Caro V, Pandey K, Cho E, and others.